Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.
  • Page:
  • 1

BTG - 60% Drop on Friday!!! (BGC)     

vas - 16 Nov 2003 00:44

BTG dropped thru' the floor on Friday due to the U.S. regulators suspending a clinical trial of its biggest new drug hope, an treatment for varicose veins...
Shares went from 380p to 154p in half an hour.
Wasn't 2 weeks ago that Investors Chronicle was predicting 700p & a 'STRONG BUY'(based on this new vaicose vein treatment launch, of course)..

Just wondering....at 154p, is it a good time to get in? I've got no idea how the US regulators work, but 'suspending' a trial doesn't sound too final to me!
Any opinions would be appreciated

Mega Bucks - 16 Nov 2003 02:40 - 2 of 9

vas

put this on my stockwatch and will watch this 1st thing monday morning it could rebound so could go long on a cfd it may have been over done????? it looks like a sound company but just pulled down by this one problem ,who nows will find out monday which way it wants to go....

Mega...

washlander - 16 Nov 2003 06:44 - 3 of 9

Concerns Varisolve, a potentialy block busting treatment for varicose veins. It involves a non surgical treatment that pumps foam into the problem veins. I think the problem is the possible side effects that it may lead to deep vein thrombosis. Which may be agravated when flying long haul ect. Personally I find flying hurts my arms ^-^

bonn1e - 17 Nov 2003 10:58 - 4 of 9

BTG PLC
14 November 2003



14 November 2003 - for immediate release



BTG plc: Statement on Varisolve(R) US Phase II safety study



BTG plc (LSE: BGC), the global technology commercialisation company, today
announced that it has been informed verbally by the US Food & Drug
Administration (FDA) of a decision to place on clinical hold a Phase II safety
study of Varisolve(R), a new treatment for varicose veins being developed by
Provensis, BTG's subsidiary.



FDA has indicated it will write to Provensis describing the reasons for placing
the study on clinical hold. BTG will make a further announcement after
receiving the FDA's letter and assessing the impact on the further clinical
development of Varisolve(R).



Ends



For further information contact:


BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741
07990 530605




This information is provided by RNS
The company news service from the London Stock Exchange

bonn1e - 17 Nov 2003 11:00 - 5 of 9

I have been informed that there are concerns about accidental injecting into arteries.

vas - 17 Nov 2003 21:20 - 6 of 9

vas - 17 Nov 2003 21:21 - 7 of 9

up 21% today... lucky I took a chance!

goldfinger - 17 Nov 2003 23:16 - 8 of 9

VAS, well done you called it right. I stayed out and am cursing myself now.

cheers GF.

Mega Bucks - 18 Nov 2003 07:01 - 9 of 9

covered +17 :-)
  • Page:
  • 1
Register now or login to post to this thread.